- Consumer/Patient Representative
- Health Plans Representative
- Provider Representative (2)
- Research Representative
- Technical Expertise, Health Exchange
- Technical Expertise, Long-Term Care
- Technical Expertise, Privacy
- Technology Vendor

For more information about the HITSC please visit: *http://healthit.gov/facas/health-it-standards-committee*

Submitting Nominations: Nominations should be submitted electronically through the application database at: *http://healthit.gov/facas/faca-workgroup-membership-application* . All nominations must be compiled and submitted in one complete package. A nomination package must include: A short bio, a current CV including contact information and memberships with professional organizations/advisory committees, and two letters of support.

Dated: February 4, 2015.

Michelle Consolazio,

FACA Program Lead, Office of Policy, Office of the National Coordinator for Health Information Technology.

[FR Doc. 2015–02885 Filed 2–11–15; 8:45 am]

BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry; Notice of Intent To Develop Set 28 Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of development.

SUMMARY: This notice announces the development of Set 28 Toxicological Profiles. Set 28 Toxicological Profiles consists of one updated profile and three new profiles. These profiles will be available to the public on or about October 17, 2015. Electronic access to these documents will be available at the ATSDR Web site: *http://www.atsdr.cdc.gov/toxprofiles/index.asp.*

FOR FURTHER INFORMATION CONTACT: Commander Jessilynn B. Taylor, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE., Mail Stop F–57, Atlanta, GA 30333, telephone 770–488–3313.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act of 1986 (SARA) (42 U.S.C. 9601 *et seq.*) amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) (42 U.S.C. 9601 *et seq.*) by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) with regard to hazardous substances that are most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the Priority List of Hazardous Substances (*www.atsdr.cdc.gov/SPL*). This list names 275 hazardous substances that pose the most significant potential threat to human health as determined by ATSDR and EPA. The availability of the revised list of the 275 priority substances was announced in the **Federal Register** on May 28, 2014 (79 FR 30613). For prior versions of the list of substances, see **Federal Register** notices dated November 3, 2011 (76 FR 68193); March 6, 2008 (73 FR 12178); December 7, 2005 (70 FR 72840 ; November 7, 2003 (68 FR 63098); October 25, 2001 (66 FR 54014); October 21, 1999 (64 FR 56792); November 17, 1997 (62 FR 61332); April 29, 1996 (61 FR 18744); February 28, 1994 (59 FR 9486); October 28, 1992 (57 FR 48801); October 17, 1991 (56 FR 52166); October 17, 1990 (55 FR 42067); October 26, 1989 (54 FR 43615); October 20, 1988 (53 FR 41280); and April 17, 1987 (52 FR 12866).

Set 28 Toxicological Profiles

The following toxicological profiles are being developed:

	Name	CAS
1	Antimony (UPDATE)	7440–36–0
2	Glyphosate	1071–83–6
3	2-4, Dichlorophenoxyacetic acid	94–75–7
4	Silica	7631–86–9

Notice of the availability of drafts of these four toxicological profiles for public review and comment will be published in the **Federal Register** on/or about October 17, 2015, with notice of a 90-day public comment period for each profile, starting from the actual release date. Following the close of the comment period, chemical-specific comments will be addressed, and, where appropriate, changes will be incorporated into each profile.

Dated: February 3, 2015.

Sascha Chaney,

Acting Director, Office of Policy Planning and Evaluation, National Center for Environmental Health/, Agency for Toxic Substances and Disease Registry.

[FR Doc. 2015–02548 Filed 2–11–15; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis (ACET)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Time and Date: 11:00 a.m.–3:30 p.m., March 3, 2015.

Place: This meeting will be accessible by Web conference. Toll-free +1 (877) 951–7311, Participant Code: 6816256.

For Participants: URL: https://www.mymeetings.com/nc/join/, Conference number: PW1126518, *Audience passcode:* 6816256.

Participants can join the event directly at: *https://www.mymeetings.com/nc/join.php?i=PW1126518&p=6816256&t=c.*

Status: Open to the public limited only by web conference. Participation by web conference is limited by the number of ports available. The meeting accommodates 100 ports.

Purpose: This council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews

the extent to which progress has been made toward eliminating tuberculosis.

Matters for Discussion: Agenda items include the following topics: (1) Update on Global TB Coordination Activities; (2) Profile of Foreign-Born TB cases; (3) Impact of funding cuts on TB programs in the field; and (4) other tuberculosis-related issues.

Agenda items are subject to change as priorities dictate. *Contact Person for More Information:* Margie Scott-Cseh, Centers for Disease Control and Prevention, 1600 Clifton Road NE., M/S E–07, Atlanta, Georgia 30333, telephone (404) 639–8317; Email: *zkr7@cdc.gov*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Catherine Ramadei,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2015–02887 Filed 2–11–15; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–N–0001]

Advisory Committee Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.).

DATES: Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Cardio and Renal Drugs Advisory Committee.	August 27, 2016.
Endocrinologic and Metabolic Drugs Advisory Committee.	August 27, 2016.
Oncologic Drugs Advisory Committee.	September 1, 2016.
Anti-Infective Drugs Advisory Committee.	October 7, 2016.
Dermatologic and Ophthalmic Drugs Advisory Committee.	October 7, 2016.
Cellular, Tissue, and Gene Therapies Advisory Committee.	October 28, 2016.
Technical Electronic Product Radiation Safety Standards Committee.	December 24, 2016.

FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–443–0572 or 1–800–741–8138. For further information related to FDA advisory committees, please visit us at *http://www.fda.gov/AdvisoryCommittees/default.htm.*

Dated: February 6, 2015.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2015–02909 Filed 2–11–15; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–D–0152]

Alcoholism: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ''Alcoholism: Developing Drugs for Treatment.'' The purpose of this guidance is to assist sponsors in the development of drugs for the treatment of alcoholism.

DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by April 13, 2015.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor, Silver Spring, MD 20993. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

Submit electronic comments on the draft guidance to *http://www.regulations.gov.* Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Rachel Skeete, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 3191, Silver Spring, MD 20993–0002, 301–796–2280.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled ''Alcoholism: Developing Drugs for Treatment.'' There is a need for additional pharmacologic treatments for alcoholism. Traditionally, alcoholism treatments have been assessed based on the number of patients who refrain from drinking altogether. Patients who attain and sustain complete abstinence from alcohol may be assumed to accrue clinical benefit. However, other patterns of drinking also may be valid surrogates for clinical benefit. This guidance provides supporting information for endpoints based on patterns of drinking that may be considered appropriate measures of clinical benefit.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the Agency's current thinking on the development of drugs for the treatment of alcoholism and appropriate endpoints for clinical trials of drugs to treat alcoholism. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. The Paperwork Reduction Act of 1995

This guidance refers to previously approved collections of information that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR parts 312 and 314 have been approved under OMB